Phio Pharmaceuticals Corp. - Common Stock (PHIO)
0.7710
-0.0408 (-5.03%)
NASDAQ · Last Trade: Nov 13th, 10:58 PM EST
News & Press Releases
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) will present an overview of the Company’s INTASYL® siRNA therapeutic platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas. The presentation will be followed by a live Q&A session.
Via B2i Digital · November 12, 2026
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Highlighting Phio's Differentiated, Paradigm-Shifting Treatment Approach for Skin Cancer
Via Newsfile · November 12, 2026
Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced today that clinical data from its Phase 1b trial were presented at the 2026 Annual Meeting of the American Society for Dermatologic Surgery (ASDS), held in San Diego, California, from November 5-8, 2026.
Via B2i Digital · November 9, 2026
Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma; Potential to Decrease Morbidities and Surgical Fatigue
Via Newsfile · November 9, 2026
Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced today that it will present clinical data from its Phase 1b clinical trial at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Phoenix, Arizona from November 6-8, 2026.
Via B2i Digital · November 6, 2026
Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) today reported financial results for the quarter ended September 30, 2026, and provided a business update.
Via B2i Digital · November 6, 2026
Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma
Via Newsfile · November 6, 2026
Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
PH-762 Program Accomplishes Major Development Milestones Including Completion of Commercial-Scale cGMP Manufacturing, Treatment in Long-Term Toxicology Study, and Submission of Key Regulatory Documents to FDA
Via Newsfile · November 5, 2026
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Via Newsfile · October 19, 2026
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) today announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), representing a critical operational and strategic milestone as the Company advances PH-762 to the next stage of clinical development.
Via B2i Digital · October 13, 2026
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing...
Via Newsfile · October 13, 2026
OTC Markets Group Announces Third Annual Global Markets Forum Presentations Now Available On Demand
View presentations from European and Canadian public growth companies following the October 7–8 event
By Virtual Investor Conferences · Via GlobeNewswire · October 12, 2026
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) today announced that Robert Bitterman, President and Chief Executive Officer, will present Phio’s INTASYL® siRNA therapeutic platform at The Global Markets Virtual Forum hosted by www.VirtualInvestorConferences.com (VIC) on October 8th, 2026.
Via B2i Digital · October 6, 2026
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.com
Via Newsfile · October 6, 2026
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) today announced that it has accepted the invitation to present at the National Investment Banking Association’s (NIBA) 153rd Conference on October 6-7, 2026, in Fort Lauderdale, Florida.
Via B2i Digital · October 5, 2026
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - October 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing...
Via Newsfile · October 5, 2026
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) today announced that it will present at the Life Sciences Future 2026 Conference, taking place September 30 to October 1, 2026, at the Sheraton Valley Forge Hotel in King of Prussia, Pennsylvania.
Via B2i Digital · September 23, 2026
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing...
Via Newsfile · September 23, 2026
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
King of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Via Newsfile · September 14, 2026
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing...
Via Newsfile · September 11, 2026
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing...
Via Newsfile · August 11, 2026
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase...
Via Newsfile · August 6, 2026
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Via Newsfile · July 22, 2026
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Via Newsfile · July 22, 2026
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Via Newsfile · July 21, 2026